Initially, Zhu and collaborators evaluated the presence of miR-223 in 62 ovarian tumor tissue samples and revealed that 33 samples that were obtained from cisplatin-resistant patients displayed higher levels of miR-223 and displayed a lower expression of PTEN (phosphatase and tensin homologue), which is a known tumor suppressor gene and one of the identified targets of miR-223 [36,54]. The gene discussed is PTEN; the disease is ovarian neoplasm.